DEBIOPHARM AND NEOVACS SIGN LICENSE AGREEMENT

Debiopharm S.A., the independent drug development company specializing in oncology, endocrinology and niche products, along with its wholly owned investment affiliate, Debioinnovation, and Neovacs S.A., a French biotechnology company specializing in the development of proprietary anticytokine immunogens, has announced the signature of a license and equity agreement for the development of a TNF (tumour necrosis factor) alpha kinoid and its related technology programmes. The potential indications include wasting syndromes such as cancer cachexia and autoimmune diseases.

Yahoo News (http://biz.yahoo.com/prnews/050627/ukm014.html?.v=11)